Brilinta (ticagrelor)

pCPA File Number: 21126
Negotiation Status:
Concluded with an LOI
Indication(s):
secondary prevention of atherothrombotic events
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: